Skip to content

Book value per share at other companies

Eli Lilly logo
Eli LillyLLY
$34.82+98.9%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$8.16+190%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$0.44-60.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$23.29+2,285%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$4.12+68.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$15.79+60.9%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%
Enterprise value$1.36B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Calculated from MoonLake Immunotherapeutics’s reported figures.

Based on the most recent quarter.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's book value per share?
MoonLake Immunotherapeutics (MLTX) reported book value per share of $3.56 in Q1 2026.
How has MoonLake Immunotherapeutics's book value per share changed year-over-year?
MoonLake Immunotherapeutics's book value per share decreased by 44.7% year-over-year, from $6.44 to $3.56.
What is the long-term trend for MoonLake Immunotherapeutics's book value per share?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's book value per share has grown at a 33.5% compound annual growth rate (CAGR), from -$1.49 to $4.72.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.